HomeCompareADDXF vs GBDC

ADDXF vs GBDC: Dividend Comparison 2026

ADDXF yields 202.02% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADDXF wins by $105.68M in total portfolio value
10 years
ADDXF
ADDXF
● Live price
202.02%
Share price
$0.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$126.53M
Annual income
$64,106,411.82
Full ADDXF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — ADDXF vs GBDC

📍 ADDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADDXFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADDXF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADDXF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADDXF
Annual income on $10K today (after 15% tax)
$17,171.72/yr
After 10yr DRIP, annual income (after tax)
$54,490,450.05/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, ADDXF beats the other by $40,507,326.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADDXF + GBDC for your $10,000?

ADDXF: 50%GBDC: 50%
100% GBDC50/50100% ADDXF
Portfolio after 10yr
$73.69M
Annual income
$40,278,572.83/yr
Blended yield
54.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ADDXF
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADDXF buys
0
GBDC buys
0
No recent congressional trades found for ADDXF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADDXFGBDC
Forward yield202.02%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$126.53M$20.85M
Annual income after 10y$64,106,411.82$16,450,733.83
Total dividends collected$119.31M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ADDXF vs GBDC ($10,000, DRIP)

YearADDXF PortfolioADDXF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$30,902$20,202.02$12,492$1,791.70+$18.4KADDXF
2$91,409$58,344.23$16,527$3,160.58+$74.9KADDXF
3$259,102$161,293.94$23,588$5,904.90+$235.5KADDXF
4$704,521$427,281.62$37,141$11,901.65+$667.4KADDXF
5$1,839,646$1,085,809.10$66,205$26,463.38+$1.77MADDXF
6$4,618,204$2,649,782.60$137,452$66,612.65+$4.48MADDXF
7$11,158,255$6,216,776.60$342,372$195,298.53+$10.82MADDXF
8$25,977,314$14,037,980.69$1,053,292$686,954.33+$24.92MADDXF
9$58,339,227$30,543,501.04$4,111,439$2,984,416.95+$54.23MADDXF
10$126,529,384$64,106,411.82$20,849,974$16,450,733.83+$105.68MADDXF

ADDXF vs GBDC: Complete Analysis 2026

ADDXFStock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Full ADDXF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ADDXF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADDXF vs SCHDADDXF vs JEPIADDXF vs OADDXF vs KOADDXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.